Search Results 1721-1730 of 12406 for Sertraline

  1. Patient Stories - Dana M. Harris, M.D. - Mayo Clinic

    Search for a doctor. Dana M. Harris, M.D.. Infectious Disease Specialist; Internist. Request an Appointment · Overview · Publications. Patient Stories.

  2. Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF - Mayo Clinic

    The purpose of this study is to determine the safety and tolerability of oral GRI-0621 as assessed by clinical labs and adverse events (AEs) after 12 weeks of ...

  3. Mayo Clinic Minute: Benefits, dangers of fentanyl

    Mike Hooten, M.D. (Anethesiology, Mayo Clinic): It is many, many times more potent than morphine, oxycodone, oxycontin, Vicadin, dilaudid, hydromorphine, all ...

  4. Publications - Bart L. Clarke, M.D. - Mayo Clinic

    Hoong CWS, Sfeir JG, Tebben P, Clarke BL. Prognostic factors for refractory outcome in localizing TIO: experience in a tertiary center.

  5. Mayo Clinic

    The Future of Healthcare - Dr Anton Decker · More videos on YouTube · Fund research. Save lives. · About Mayo Clinic · Medical Professionals · Businesses · Students.

  6. Publications - Brendan C. Lanpher, M.D. - Mayo Clinic

    McNamee L, Schoch K, Huang A, Lee H, Wang LK, Smith EC, Lark RK, Buckley AF, Jobanputra V, Nelson SF, Shashi V, Undiagnosed Diseases Network. Reanalysis of RNA ...

  7. APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis - Mayo Clinic

    About this study. The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated ...

  8. Neurology - Clinical trials

    The purpose of this study is to create a repository for cerebellar ataxia and nucleotide repeat diseases in order to fully investigate the genetic and ...

  9. A Study of Patients Treated for Wiskott-Aldrich Syndrome Since 1990 - Mayo Clinic

    The retrospective and prospective portions of the study will address the impact of a number of pre and post-transplant factors on post-transplant disease ...

  10. Ustekinumab-ttwe (intravenous route, subcutaneous route) - Mayo Clinic

    Ustekinumab-ttwe injection is used to treat moderate to severe plaque psoriasis in patients who may benefit from receiving phototherapy (ultraviolet light ...